TIANYUAN HEALTH (00557) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of HK$8.436 million, representing a decrease of 43.23% compared to the same period last year. The loss attributable to equity holders was HK$3.065 million, down 45.33% year-on-year. Loss per share was HK$0.77 cents.

According to the announcement, the reduction in loss was primarily due to a decrease of approximately HK$600,000 in net realized and unrealized valuation losses from securities trading during the period, a reversal of expected credit losses of approximately HK$2.5 million during the period, and the transformation of net realized and unrealized foreign exchange losses of approximately HK$1.9 million in the same period last year into net realized and unrealized foreign exchange gains of approximately HK$2.7 million during the current period. These positive factors were partially offset by a decrease in total revenue of approximately HK$6.4 million.